J. Straimer

发表

The Plasmodium PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites

G. Bonamy, D. Fidock, F. Nosten, 2017, Scientific Reports.

Plasmodium falciparum K13 Mutations Differentially Impact Ozonide Susceptibility and Parasite Fitness In Vitro

D. Fidock, Nina F. Gnädig, J. Straimer, 2017, mBio.

TARGETING THE CELL STRESS RESPONSE OF PLASMODIUM FALCIPARUM TO OVERCOME ARTEMISININ RESISTANCE

Zbynek Bozdech, L. Tilley, D. Fidock, 2015 .

Generation of Transgenic Human Malaria Parasites With Strong Fluorescence in the Transmission Stages

D. Fidock, P. Sinnis, G. Mlambo, 2018, bioRxiv.

A G358S mutation in the Plasmodium falciparum Na+ pump PfATP4 confers clinically-relevant resistance to cipargamin

K. Kirk, Adele M. Lehane, G. V. van Dooren, 2022, Nature Communications.

A conserved metabolic signature associated with response to fast-acting antimalarial agents

M. Barrett, A. Waters, C. Regnault, 2022, bioRxiv.

Artemisinin Action and Resistance in Plasmodium falciparum.

Leann Tilley, S. Ralph, L. Tilley, 2016, Trends in parasitology.

Balancing drug resistance and growth rates via compensatory mutations in the Plasmodium falciparum chloroquine resistance transporter

G. Johnston, Adele M. Lehane, D. Fidock, 2015, Molecular microbiology.

High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine

E. Schmitt, J. Straimer, Katalin Csermak Renner, 2021, The Journal of infectious diseases.

A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms.

C. Rogier, D. Fidock, B. Pradines, 2016, The New England journal of medicine.

Genome-wide screen identifies new candidate genes associated with artemisinin susceptibility in Plasmodium falciparum in Kenya

Samuel A. Assefa, D. Kwiatkowski, M. Manske, 2013, Scientific Reports.

Charles Darwin University Genome-wide screen identifies new candidate genes associated with artemisinin susceptibility in Plasmodium falciparum in Kenya Borrmann,

Samuel A. Assefa, D. Kwiatkowski, M. Manske, 2013 .

Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies

Adele M. Lehane, Rowena E. Martin, D. Fidock, 2016, Nature Communications.

The Plasmodium PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites

G. Bonamy, D. Fidock, F. Nosten, 2017, Scientific Reports.

A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance

David M. Shackleford, R. Price, D. Fidock, 2017, Nature Communications.

Insights into the intracellular localization, protein associations and artemisinin resistance properties of Plasmodium falciparum K13

D. Fidock, Rachel L. Edwards, Marcus C. S. Lee, 2020, PLoS pathogens.

K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates

D. Fidock, Lei Zhang, P. Gregory, 2015, Science.

P. falciparum K13 mutations present varying degrees of artemisinin resistance and reduced fitness in African parasites

P. Rosenthal, D. Fidock, L. Ross, 2021, bioRxiv.

Artemisinin resistance phenotypes and K13 inheritance in a Plasmodium falciparum cross and Aotus model

Min Zhang, Juliana M. Sá, Thomas E. Wellems, 2018, Proceedings of the National Academy of Sciences.

Discovery and Preclinical Pharmacology of INE963, a Potent and Fast-Acting Blood-Stage Antimalarial with a High Barrier to Resistance and Potential for Single-Dose Cures in Uncomplicated Malaria

F. Gamo, E. Fang, Yen-Liang Chen, 2022, Journal of medicinal chemistry.

Efficacy of Cipargamin (KAE609) in a Randomized, Phase II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated Plasmodium falciparum Malaria

Kwaku Poku Asante, E. Karita, A. Oduro, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness

D. Fidock, L. Ross, F. Nosten, 2021, eLife.

In vivo and in vitro efficacy of amodiaquine against Plasmodium falciparum in an area of continued use of 4-aminoquinolines in East Africa.

M. Pirmohamed, A. Nzila, B. Lowe, 2009, The Journal of infectious diseases.

Generation of Transmission-Competent Human Malaria Parasites with Chromosomally-Integrated Fluorescent Reporters

D. Fidock, P. Sinnis, G. Mlambo, 2019, Scientific Reports.

Editing the Plasmodium vivax genome, using zinc-finger nucleases.

Juliana M. Sá, D. Fidock, T. Wellems, 2015, The Journal of infectious diseases.

Site-specific genome editing in Plasmodium falciparum using engineered zinc-finger nucleases

M. Llinás, D. Fidock, B. Zeitler, 2012, Nature Methods.

Plasmodium falciparum K13 mutations in Africa and Asia present varying degrees of artemisinin resistance and an elevated fitness cost in African parasites

P. Rosenthal, D. Fidock, L. Ross, 2021, bioRxiv.

Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose–Efficacy Modeling

R. Price, D. Fidock, R. Sinden, 2016, PLoS medicine.

A conserved metabolic signature associated with response to fast-acting anti-malarial agents

C. Regnault, T. Diagana, J. Straimer, 2023, Microbiology spectrum.

Targeting the Cell Stress Response of Plasmodium falciparum to Overcome Artemisinin Resistance

Zbynek Bozdech, D. Fidock, S. Foote, 2015, PLoS biology.

High prevalence of P. falciparum K13 mutations in Rwanda is associated with slow parasite clearance after treatment with artemether-lumefantrine

E. Schmitt, J. Straimer, P. Gandhi, 2021 .

Balancing drug resistance and growth rates via compensatory mutations in the Plasmodium falciparum chloroquine resistance transporter

G. Johnston, Adele M. Lehane, D. Fidock, 2015, Molecular microbiology.